Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT
January 02 2018 - 4:30PM
Business Wire
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS -
Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused
on developing immunotherapies based on gene-edited allogeneic CAR
T-cells (UCART), announced today that Dr. André Choulika, Chairman
and Chief Executive Officer of Cellectis, will present at the 36th
Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018
at 12:00 p.m. Pacific Time in the Elizabethan A/B room. A Q&A
session will follow at 1:30 p.m. PT in the Sussex room. The
conference will be held from January 8 to 11, 2018 at the Westin
St. Francis Hotel in San Francisco, CA.
To access the live webcast of Cellectis presentation and
subsequent breakout session, please visit
http://www.cellectis.com/en/agenda/. A replay of the webcast will
be available on Cellectis website for 90 days.
About Cellectis
Cellectis is a clinical-stage biopharmaceutical company focused
on developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing – built on its flagship TALEN® technology
and pioneering electroporation system PulseAgile – Cellectis uses
the power of the immune system to target and eradicate cancer
cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on
the NYSE Alternext market (ticker: ALCLS). To find out more about
us, visit our website: www.cellectis.com.
Talking about gene editing? We do it. TALEN® is a registered
trademark owned by the Cellectis Group.
Disclaimer
This press release contains “forward-looking” statements that
are based on our management’s current expectations and assumptions
and on information currently available to management.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Further information on the risks
factors that may affect company business and financial performance,
is included in filings Cellectis makes with the Security Exchange
Commission from time to time and its financial reports. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180102005831/en/
CellectisMedia:Jennifer Moore, 917-580-1088VP of
Communicationsmedia@cellectis.comorCaitlin Kasunich,
212-896-1241KCSA Strategic
Communicationsckasunich@kcsa.comorIR:Simon Harnest,
646-385-9008VP of Corporate Strategy and
Financesimon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From May 2023 to May 2024